PT  - JOURNAL ARTICLE
AU  - Vanessa Gonzalez-Covarrubias
AU  - Jianping Zhang
AU  - James L. Kalabus
AU  - Mary V. Relling
AU  - Javier G. Blanco
TI  - Pharmacogenetics of Human Carbonyl Reductase 1 (<em>CBR1</em>) in Livers from Black and White Donors
AID  - 10.1124/dmd.108.024547
DP  - 2009 Feb 01
TA  - Drug Metabolism and Disposition
PG  - 400--407
VI  - 37
IP  - 2
4099  - http://dmd.aspetjournals.org/content/37/2/400.short
4100  - http://dmd.aspetjournals.org/content/37/2/400.full
SO  - Drug Metab Dispos2009 Feb 01; 37
AB  - Carbonyl reductase 1 (CBR1) reduces the anticancer drug doxorubicin into the cardiotoxic metabolite doxorubicinol. We documented the hepatic expression of CBR1 in samples from white and black donors. Concordance between ethnicity and geographical ancestry was examined with ancestry informative markers. Livers from blacks and whites showed similar CBR1 mRNA levels (CBR1 mRNAblacks = 4.8 ± 4.3 relative -fold versus CBR1 mRNAwhites = 3.6 ± 3.6 relative -fold; p = 0.217). CBR1 protein levels did not differ between both groups (CBR1blacks = 8.0 ± 3.4 nmol/g cytosolic protein versus CBR1whites = 9.0 ± 4.6 nmol/g cytosolic protein; p = 0.347). The CBR1 3′-untranslated region polymorphism 1096G>A was detected in DNA samples from whites (p = 0.875; q = 0.125), and livers with homozygous G/G genotypes showed a trend toward higher CBR1 mRNA levels compared with samples with heterozygous G/A genotypes [CBR1 1096G>A(G/G) = 4.1 ± 4.1 relative -fold versus CBR1 1096G>A(G/A) = 3.0 ± 2.5 relative-fold; p = 0.266]. CBR1 1096G>A genotype status was associated with CBR1 protein levels (p = 0.030) and CBR activity expressed as the rate of synthesis of doxorubicinol (p = 0.028). Our findings warrant further studies to evaluate the impact of CBR1 1096G>A genotype status on the variable pharmacodynamics of anthracycline drugs. The American Society for Pharmacology and Experimental Therapeutics